Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.74 |
| ▸ | HTT | P42858 | 3/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.64 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | DHODH | Q02127 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20990440 | 1.00 | ALDH1A1 (0.74) | ALDH1A1HTTTSHRHPGDTAOK1 | |
| Hydrochloric Acid SCHEMBL7797522 | 0.99 | ALDH1A1 (0.72) | ALDH1A1HTTTSHRHPGDTAOK1 | |
| SCHEMBL26779718 | 0.91 | ALDH1A1 (0.61) | ALDH1A1HTTTSHRHPGDTAOK1 | |
| SCHEMBL7445856 | 0.91 | ALDH1A1 (0.61) | ALDH1A1HTTTSHRHPGDTAOK1 | |
| SCHEMBL17335683 | 0.91 | ALDH1A1 (0.61) | ALDH1A1HTTTSHRHPGDTAOK1 | |
| SCHEMBL1565743 | 0.89 | ALDH1A1 (0.76) | ALDH1A1HTTTSHRHPGDMEN1 | |
| SCHEMBL2406505 | 0.89 | ALDH1A1 (0.76) | ALDH1A1HTTTSHRHPGDMEN1 | |
| SCHEMBL3330158 | 0.86 | MEN1 (0.71) | ALDH1A1HTTTSHRHPGDTAOK1 | |
| SCHEMBL3725239 | 0.86 | ALDH1A1 (0.68) | ALDH1A1HTTTAOK1TAOK3 | |
| SCHEMBL3729153 | 0.85 | ALDH1A1 (0.74) | ALDH1A1HTTTSHRHPGDTAOK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799637-A1 | SUBSTITUTED SULFONAMIDOPROPIONAMIDES AND METHODS OF USE | Amgen, Inc (US) | 2007-06-27 | — | — | EP | claimed |
| WO-2006036664-A1 | SUBSTITUTED SULFONAMIDOPROPIONAMIDES AND METHODS OF USE | AMGEN INC. (US) | 2006-04-06 | — | — | WO | claimed |
| WO-2023234410-A1 | INHIBITORY AGENT FOR MYOCARDIAL CELL DEATH, AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR MYOCARDIAL DISORDERS OR HEART FAILURE | 京都府公立大学法人 | 2023-12-07 | — | — | WO | disclosed |
| US-10703754-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | ELI LILLY AND COMPANY (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2019-06-27 | — | — | US | disclosed |
| US-20180265511-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2018-09-20 | — | — | US | disclosed |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
| US-8679984-B2 | Method of manufacturing electric device, array of electric devices, and manufacturing method therefor | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2014-03-25 | — | — | US | disclosed |
| US-20130059869-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | HYDRA BIOSCIENCES, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130001554-A1 | Method Of Manufacturing Electric Device, Array Of Electric Devices, And Manufacturing Method Therefor | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-01-03 | — | — | US | disclosed |
| WO-2012175654-A1 | TETRALINE SULFONAMIDE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | FACULTES UNIVERSITAIRES NOTRE-DAME DE LA PAIX (BE) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012175654-A1 | TETRALINE SULFONAMIDE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | FACULTES UNIVERSITAIRES NOTRE-DAME DE LA PAIX (BE) | 2012-12-27 | — | — | WO | disclosed |
| US-20120046305-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | ELI LILLY AND COMPANY | 2012-02-23 | — | — | US | disclosed |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2009-06-04 | — | — | US | disclosed |
| US-7488730-B2 | N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-phenyl-1-piperazinealkylamide derivatives, and therapeutic use thereof as 5-HT7 receptor ligands | UNIVERSITA DEGLI STUDI DI BARI (IT) | 2009-02-10 | — | — | US | disclosed |
| EP-1856074-A2 | SUBSTITUTED ARYL OR HETEROARYLSULFONYLBUTANAMIDES FOR USE AS ANTI-INFLAMMATORY AGENTS | Amgen, Inc (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1799637-A1 | SUBSTITUTED SULFONAMIDOPROPIONAMIDES AND METHODS OF USE | Amgen, Inc (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20070117811-A1 | N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-phenyl-1-piperazinealkylamide derivatives, and therapeutic use thereof as 5-HT7 receptor ligands | UNIVERSITA DEGLI STUDI DI BARI (IT) | 2007-05-24 | — | — | US | disclosed |
| WO-2006041888-A2 | SUBSTITUTED ARYL OR HETEROARYLSULFONYLBUTANAMIDES FOR USE AS ANTI-INFLAMMATORY AGENTS | AMGEN INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006036664-A1 | SUBSTITUTED SULFONAMIDOPROPIONAMIDES AND METHODS OF USE | AMGEN INC. (US) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703754-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | ELANE, CASP3, MMP8 | ALDH1A1 1104/4885HTT 4377/4885TSHR 4745/4885 |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | ALDH1A1 968/4885HTT 160/4885TSHR 3225/4885 |
| US-20180265511-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | ALDH1A1 1104/4885HTT 4377/4885TSHR 4745/4885 |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | ALDH1A1 968/4885HTT 160/4885TSHR 3225/4885 |
| US-20120046305-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | TRPA1, TRPV1, TRPV3 | ALDH1A1 1173/4885HTT 1239/4885TSHR 3294/4885 |
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | ALDH1A1 1104/4885HTT 4377/4885TSHR 4745/4885 |
| US-20070117811-A1 | N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-phenyl-1-piperazinealkylamide derivatives, and therapeutic use thereof as 5-HT7 receptor ligands | HTR7, HTR3A, HTR1E | ALDH1A1 3094/4885HTT 927/4885TSHR 615/4885 |
| US-20130059869-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | ALDH1A1 968/4885HTT 160/4885TSHR 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.